LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Arvinas Inc

Suletud

SektorTervishoid

7.53 9.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.02

Max

7.56

Põhinäitajad

By Trading Economics

Sissetulek

128M

83M

Müük

130M

189M

Aktsiakasum

1.14

Kasumimarginaal

43.909

Töötajad

430

EBITDA

129M

73M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+109.97% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-98M

535M

Eelmine avamishind

-1.6

Eelmine sulgemishind

7.53

Uudiste sentiment

By Acuity

53%

47%

323 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Arvinas Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. mai 2025, 18:41 UTC

Suurimad hinnamuutused turgudel

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

Võrdlus sarnastega

Hinnamuutus

Arvinas Inc Prognoos

Hinnasiht

By TipRanks

109.97% tõus

12 kuu keskmine prognoos

Keskmine 14.53 USD  109.97%

Kõrge 24 USD

Madal 8 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Arvinas Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

19 ratings

10

Osta

9

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.55 / 9.11Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

323 / 380 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.